MBB Public Markets I LLC Buys New Holdings in United Therapeutics Co. (NASDAQ:UTHR)

MBB Public Markets I LLC purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 3,386 shares of the biotechnology company’s stock, valued at approximately $1,079,000.

Other institutional investors also recently bought and sold shares of the company. ClariVest Asset Management LLC increased its stake in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the period. V Square Quantitative Management LLC purchased a new stake in United Therapeutics in the second quarter valued at $30,000. Innealta Capital LLC acquired a new stake in United Therapeutics during the 2nd quarter worth about $33,000. Rise Advisors LLC purchased a new position in shares of United Therapeutics during the 1st quarter valued at about $32,000. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in shares of United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Down 0.1 %

UTHR stock opened at $358.35 on Tuesday. The stock has a market capitalization of $15.89 billion, a P/E ratio of 16.94, a P/E/G ratio of 1.30 and a beta of 0.57. The firm has a 50-day simple moving average of $342.59 and a 200-day simple moving average of $296.92. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $366.08.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period in the prior year, the firm earned $5.24 EPS. Equities analysts forecast that United Therapeutics Co. will post 24.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the topic of several analyst reports. Bank of America dropped their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. Jefferies Financial Group boosted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a research report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $357.17.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $45,293.30. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $45,293.30. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $40,622.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 107,652 shares of company stock valued at $35,785,807. Corporate insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.